Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0S9MU
|
|||
| Former ID |
DAP000220
|
|||
| Drug Name |
Rizatriptan
|
|||
| Synonyms |
Risatriptan; Rizatriptanum; Rizatriptan benzoat; MK 462 free base; Maxalt (TN); Rizaliv (TN); Rizalt (TN); Rizatriptan (INN); Rizatriptan [INN:BAN]; N,N-Dimethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indole-3-ethanamine; N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanamine; N,N-Dimethyl-2-[5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine; N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]-ethanamine; N,N-dimethyl-2-[5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanamine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Migraine [ICD-11: 8A80; ICD-10: G43, G43.9; ICD-9: 346] | Approved | [1] | |
| Therapeutic Class |
Antiinflammatory Agents
|
|||
| Company |
Merck & Co
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H19N5
|
|||
| Canonical SMILES |
CN(C)CCC1=CNC2=C1C=C(C=C2)CN3C=NC=N3
|
|||
| InChI |
1S/C15H19N5/c1-19(2)6-5-13-8-17-15-4-3-12(7-14(13)15)9-20-11-16-10-18-20/h3-4,7-8,10-11,17H,5-6,9H2,1-2H3
|
|||
| InChIKey |
ULFRLSNUDGIQQP-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 144034-80-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7380056, 7980527, 8153125, 15221855, 26612819, 26749916, 29224147, 46506557, 46530620, 48416524, 49830967, 49984083, 50173225, 57322597, 85209524, 92718843, 93166519, 96025171, 99373553, 103236413, 103941727, 104308214, 125001917, 125728524, 126621280, 126658125, 126667003, 129384422, 131299041, 134337535, 134358454, 135110600, 135650905, 135684127, 136375513, 137002445, 139157639, 143494842, 144205087, 152036015, 152239970, 160964292, 162011662, 172091432, 174007052, 174477513, 174527522, 175266240, 176484738, 179116883
|
|||
| ChEBI ID |
CHEBI:48273
|
|||
| ADReCS Drug ID | BADD_D01957 ; BADD_D01958 | |||
| SuperDrug ATC ID |
N02CC04
|
|||
| SuperDrug CAS ID |
cas=144034800
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides coprophilus DSM 18228
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Rizatriptan benzoate can be metabolized by Bacteroides coprophilus DSM 18228 (log2FC = -0.54; p = 0.025). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 5-HT 1D receptor (HTR1D) | Target Info | Agonist | [3] |
| KEGG Pathway | cAMP signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Serotonergic synapse | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| 5HT1 type receptor mediated signaling pathway | ||||
| Reactome | Serotonin receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | Serotonin HTR1 Group and FOS Pathway | |||
| Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of Intelgenx. | |||
| REF 2 | Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019 Jun;570(7762):462-467. | |||
| REF 3 | An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc. 2002;45:199-210. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.